Sponsored by Indivumed Therapeutics 6 Jun 2023 Optimizing early discovery by unraveling cancer complexity within precision therapeutics June 6, 2023 - 7 minutesmins - By Sudha Sundaram Share WhatsApp Twitter Linkedin Email
News and Trends 31 May 2023 Artificial intelligence combats lethal superbug, new antibiotic discovered A new antibiotic called abaucin that can kill a deadly, drug-resistant pathogen has been discovered with the help of artificial intelligence (AI). Research published in Nature Chemical Biology showed that AI was able to rapidly screen 7,500 molecules that were found to inhibit the growth of the superbug Acinetobacter baumannii, a task that would be […] May 31, 2023 - 3 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 16 May 2023 LabGenius looks to create molecules with huge increase in tumor killing ability LabGenius, which uses machine learning (ML) for antibody discovery, has presented data in a poster presentation at the Protein Engineering and Biotherapeutics (PEGS) annual meeting. The data were from LabGenius’ T-cell engager (TCE) lead optimization platform, which delivered highly potent and efficacious single-domain antibodies with best-in-class killing selectivity. Optimizing antibody therapeutics across multiple properties is […] May 16, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 May 2023 Achilles Therapeutics’ new platform identifies most potent T-cell antigens Achilles Therapeutics plc says its newly-developed AI application, trained with proprietary real-world data, outperformed current AI and non-AI methods for neoantigen immunogenicity prediction in a recent analysis, enabling the identification of the most potent clonal neoantigens for personalized cancer therapies. Further details of the company’s AI-powered PELEUS bioinformatics platform are expected to be presented at […] May 12, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 May 2023 Recursion boosts drug discovery with Cyclica and Valence acquisitions Recursion has signed agreements to acquire two companies in the AI-enabled drug discovery space: Cyclica, for $40 million, and Valence, for $47.5 million. Chris Gibson, co-founder and CEO of Salt Lake City headquartered Recursion, said: “Recursion has pioneered the massive, parallel generation of -omics data with machine learning in order to map and navigate biology […] May 9, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Interview 2 May 2023 Generative AI in novel drug development Within months of its release, ChatGPT is finding use in almost all industries, including biotech, pharma, and healthcare. ChatGPT and other large language models like it belong to a family of artificial intelligence (AI) technologies dubbed generative AI. Based on statistical associations gathered from large datasets, generative AI models produce content similar to the data […] May 2, 2023 - 4 minutesmins - By Sachin Rawat Share WhatsApp Twitter Linkedin Email
Podcast 28 Apr 2023Beyond Biotech podcast 43 This week’s podcast is sponsored by Scientist.com. The mainstream media in the past couple of months has picked up on artificial intelligence (AI). The coverage concentrates not so much on its uses, more it highlights the potential for conflict, and fears over AI developing too quickly, or ‘taking over humanity.’ Debates have sprung up around […] April 28, 2023 Share WhatsApp Twitter Linkedin Email
News and Trends 27 Apr 2023 Australian biopharma Telix banks on AI with Dedicaid acquisition Australian biopharma company Telix Pharmaceuticals Limited is expanding its artificial intelligence (AI) capability with the signing of an agreement to acquire Austria-based Dedicaid GmbH, a spin-off of the Medical University Vienna. Dedicaid’s core asset is a clinical decision support software (CDSS) AI platform capable of rapidly generating indication-specific CDSS applications from available datasets, for use […] April 27, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Apr 2023 Can artificial intelligence predict future pandemics? Before the first cases of COVID-19 became known, an algorithm based on artificial intelligence developed by a company in Canada had already detected a new virus spreading across the Chinese city of Wuhan. This demonstration of the potential of new technologies applied to predicting future epidemics led a group of researchers at the Universitat Oberta […] April 21, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Expert Advice 18 Apr 2023 Pharmacovigilance – how to deal with the data By Axel Hagel, practice leader, PV & RM services, IQVIA Life science data, especially safety data, is exploding. It is estimated that pharmaceutical data is increasing at a rate of 36% annually. This is more than other data-driven industries including finance (26% YoY) and manufacturing (30% YoY). This increase is in part due to digital […] April 18, 2023 - 6 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 13 Apr 2023 Adaptyv Bio launches to ‘change protein engineering’ AI tools like ChatGPT are revolutionizing how the world generates text, images and code. In a similar way, machine learning algorithms and generative AI are upending traditional processes in life sciences and collapsing time frames in drug discovery and materials development. AlphaFold by DeepMind is probably the most well-known machine learning model in this space. […] April 13, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 11 Apr 2023 PsychoGenics launches eCube AI platform for drug discovery PsychoGenics Inc. has launched eCube, a pharmaco-electroencephalography (pharmacoEEG) platform to support phenotypic drug discovery. The company said that unlike traditional target-based drug discovery, this technique can identify novel treatments with multiple targets. Similar to the company’s AI-enabled, behavior-based platform, SmartCube, eCube harnesses machine learning to identify central nervous system (CNS) penetrant compounds and predict their […] April 11, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email